The Lancet Oncology in conversation with

By: The Lancet Group
Listen for free

  • Summary

  • Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
    © 2024 The Lancet Group
    Show more Show less
Biological Sciences Hygiene & Healthy Living Physical Illness & Disease
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

    Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
    Oct 30 2024

    Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

    Read the full Articles here:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
    15 mins
  • Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

    Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
    Sep 30 2024

    Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.

    Read the full Article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
    17 mins
  • May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

    May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
    Sep 30 2024

    May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.

    Read the Commission:
    https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
    41 mins

What listeners say about The Lancet Oncology in conversation with

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available